23
Participants
Start Date
January 26, 2018
Primary Completion Date
March 14, 2020
Study Completion Date
June 1, 2021
Itacitinib
Itacitinib self-administered orally once daily .
Ruxolitinib
Ruxolitinib self-administered orally at the stable dose of \< 20 mg daily established before entering the study.
Hanusch Hospital, Vienna
UMC Utrecht Department of Hematology, Utrecht
Ordensklinikum Linz GmbH, Servicestelle für Studien, Linz
Maastricht University Medical Center, Maastricht
Consultants in Medical Oncology and Hematology, PC, Broomall
University of Virginia, Charlottesville
Duke University Medical Center, Durham
Cleveland Clinic, Cleveland
Parkview Research Center, Fort Wayne
Providence Cancer Center, Southfield
University of Michigan Cancer Center, Ann Arbor
Nebraska Cancer Specialist, Omaha
Texas Oncology - Tyler, Tyler
Texas Oncology San Antonio, San Antonio
Texas Oncology - Round Rock Cancer Center, Round Rock
Anschutz Cancer Pavilion - University Of Colorado, Aurora
Rocky Mountain Cancer Center, Denver
Rocky Mountain Cancer Center, Colorado Springs
Arizona Oncology Associates, Tempe
University Of New Mexico Cancer Center, Albuquerque
UC Irvine Medical Center, Orange
Willamette Valley Cancer Institute, Eugene
Norwalk Hospital, Norwalk
Paracelsus Medical University Salzburg, Salzburg
VU Medical Center, Amsterdam
Erasmus Medical Center, Rotterdam
Lead Sponsor
Incyte Corporation
INDUSTRY